All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion ...
Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell lymphoma or cutaneous T-cell ... or absence (Cohort B) of ...
The early research, presented at the 66th American Society of Haematology (ASH) Annual Meeting and Exposition (Abstract 4), suggests a potentially economical way to enhance CAR T cell function and ...
By exploring the conservation and functional diversity of RIPK3 and related RHIM-containing proteins across vertebrates, this important work sheds light on the e ...
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) ...
Hybrid vehicles have gained significant market share in the US, while battery electric vehicle sales have slowed down.
BERLIN, Germany I 4, 2024 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...
Researchers find that SARS-CoV-2 spike protein persists in the skull-meninges-brain axis, driving neuroinflammation, ...
SF is a 50-year-old woman, counseled about the therapeutic use of psilocybin by her neurologist, who has participated in ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a respiratory illness with systemic immune cell activation, inflammation, widespread multiorgan dysfunction, and thrombosis.
SINGAPORE I5, 2024 I SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for ...
Herpes simplex virus (HSV), the viral agent causing human genital herpes, recurs easily and poses significant harm to patients, while also being associated with atherosc ...